GlobeNewswire Inc.··Hagens BermanImmunityBio Plummets 21% After FDA Warning Letter Over Misleading Cancer Drug Claims
ImmunityBio faces securities lawsuit after FDA warning letter over misleading Anktiva efficacy claims. Stock plunged 21%, erasing $2 billion in market value.
IBRXsecurities class actionstock price decline